Proposed investigations (findings) in the diagnosis of Stills disease: - CRP, ESR, Ferritin (high) - W/U for infection, cancer (negative) - Serologies (negative) - consider Imaging (CXR, CT, US, PET) https://t.co/l3yqAx6PA0 https://t.co/Sg7okwKHaw

Guidelines for MAS complicating Systemic JIA: Dx is based on: - Fever in sJIA with ^ ferritin > 684, plus - Any 2 of these: elevated PLTs, AST, Triglycerides or low Fibrinogen https://t.co/aIEvxRYZca https://t.co/DYpLHxRCzI

Cyclic GMP–AMP synthase (cGAS) engages stimulator of interferon genes (STING) to trigger inflammatory cytokines & type I interferons. cGAS–STING activation by genomic or mitochondrial self DNA implicated in autoinflammatory & autoimmune dz https://t.co/7CEFt9wLrl https://t.co/HpHhjJOATd

Five Mistakes When Diagnosing Still’s Disease AOSD is likely to be the adult continuum of systemic-onset juvenile arthritis (sJIA) and hence, frequently affects young men and women below the age of 35 years. https://t.co/C9kUOpFIlc https://t.co/82GIA7hSJl

Tofacitinib had faster and larger impact on improvement of fatigue compared to placebo in treatment of ankylosing spondylitis pts. Note 100% fatigue resolution roughly same vs. placebo @RheumNow #EULAR2022 ABST#POS0305 cc: @doctorRBC : https://t.co/sodp75Nblw

Li et al. Orelabrutinib in SLE. 60 patient phase 2 RCT. Week 12 SRI(4) 50.0%/61.5%/64.3% in orelabrutinib groups vs 35.7% PBO. @RheumNow #EULAR2022 LB0005 https://t.co/wWJhlY5IYW cc: @RichardPAConway : https://t.co/2IAURdfAOB

#EULAR2022 Prof Schulze-Koops highlighted a mechanistic study that baricitinib therapy ex vivo suppressed autophagy, increased apoptosis, and reduced expression of adhesion molecules in #sjogren salivary glands. Next step should be randomised controlled trial cc: @Yuz6Yusof https://t.co/1tDBNzTuwQ

In vitro study shows Upadacitinib inhibits enthesis T cell derived TNFa and IL-17A, disrupting the prominent IL-23/IL-17/TNFa axis driving SpA. @RheumNow #EULAR2022 ABST#POS0331 cc: @doctorRBC https://t.co/M8YYAOBVat

#OP0004 #EULAR2022 In line with EULAR President’s preech to go Digital, Prof Mosca highlighted a study which showed assessment of joints in RA could be done by taking photos and analysed their dorsal skin folds using convolutional neural network cc: @Yuz6Yusof : https://t.co/mn48vXtGad

Bimekizumab: IL-17A and F inhibitor for tx of PsA - BE OPTIMAL trial reached primary endpoint: ACR50 44% vs. placebo Efficacy as early as 2 weeks No MACE, uveitis, IBD, deaths @RheumNow #EULAR2022 ABST#LB0001 cc:@doctorRBC : https://t.co/wgeBsfdQcL

Prof Hoi @alberta_hoi Anti-Sm in SLE. Present in 17%. Assoc severe disease activity, "classic" SLE manifestations, specific serologic and proteomic profile. Argues for Sm+ SLE being a specific subset (or even a "different" disease?) #EULAR2022 POS0774. cc: @RichardPAConway https://t.co/cwp6q4kouz